Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints – – Preliminary safety data support a favorable benefit-risk profile at both dose levels – – Ozurdex + difluprednate identified as potential "go-forward" prophylaxis – – The vast majority of patients on the "go-forward" regimen had no inflammation and >90% of patients have no or minimal inflammation ...